EU clears Suzano–Kimberly-Clark’s $3.4B tissue JV, but UK review remains

A clean EU clearance matters because the Commission did not attach remedies to its antitrust approval. That removes a major Brussels-level merger-control uncertainty, even though it does not end reviews in every jurisdiction.

Why Brussels found no competition concern

The main competition question was vertical: Suzano is a major upstream pulp supplier, while Kimberly-Clark’s contributed business operates downstream in tissue and professional products. The European Commission said rival tissue producers in the EU would continue to have access to sufficient supplies of bleached eucalyptus kraft pulp, a pulp grade used in tissue and writing paper, despite Suzano’s position as the leading supplier worldwide.

MLex described the same rationale in practical terms: rival tissue makers would still have sufficient alternative pulp suppliers to choose from if Suzano tried to restrict supply, and the Commission found no significant competition concern from that scenario. That is the key reason the approval was unconditional rather than tied to divestitures or conduct commitments.

How big the new tissue platform would be

This is not a narrow single-country carve-out. The announced venture would own Kimberly-Clark’s international tissue assets, including 22 manufacturing facilities, approximately 9,000 employees and regional and global brands such as Kleenex, Scott and WypAll across more than 70 countries.

Industry coverage has described the manufacturing footprint as 22 facilities in 14 countries across Europe, Asia, the Middle East, South America, Central America, Africa and Oceania. Manufacturing Dive also reported that the new entity would be based in the Netherlands and include facilities across those broad regions.

Brands and assets: what is clearly in scope

The clearest brand examples in the deal materials are Kleenex, Scott and WypAll, which are named as brands the new company would market and sell. The asset perimeter is Kimberly-Clark’s international tissue assets and substantially all of its International Family Care and Professional business, not Kimberly-Clark’s entire global portfolio.

That distinction matters. Some financial coverage identifies Kimberly-Clark as the maker of Kleenex and Huggies, but the transaction sources cited here do not provide a complete brand-by-brand transfer schedule and should not be read as proof that every Kimberly-Clark brand or product line moves into the venture.

What Kimberly-Clark keeps

Kimberly-Clark is not simply walking away. It will retain a 49% stake in the new company, while Suzano takes the 51% majority interest described in the transaction announcement. Kimberly-Clark framed the partnership as part of a strategy to sharpen its focus on higher-growth, higher-margin businesses while contributing substantially all IFP assets to the venture.

The available sources do not list every Kimberly-Clark operation that remains outside the joint venture. The safest conclusion is narrower: Kimberly-Clark keeps a minority economic interest in the new tissue company and remains outside the contributed IFP perimeter with businesses that are not fully mapped in the cited materials.

The remaining UK review

EU approval does not bind the UK regulator. The CMA’s official timetable shows an invitation to comment from January 30 to February 20, 2026, the launch of the merger inquiry on March 27, 2026, and a statutory Phase 1 decision deadline of May 28, 2026, subject to limited possible extensions.

At that Phase 1 point, the CMA must decide whether the transaction can be cleared or may need a deeper Phase 2 investigation. That makes the UK review the most visible remaining antitrust checkpoint in the provided record.

What it means now

For Suzano, Brussels’ decision clears a major regulatory obstacle to taking 51% of Kimberly-Clark’s international tissue venture. For Kimberly-Clark, the deal would monetize a majority interest in its international tissue assets while retaining a 49% stake in the new entity.

For competitors, the decisive signal is about pulp access. The Commission did not see enough risk that Suzano’s position in bleached eucalyptus kraft pulp would leave rival tissue makers without adequate alternatives in the EU.

The bottom line: the EU has issued a clean antitrust green light, but the transaction is not past every regulatory hurdle. The next key date in the public record is the UK CMA Phase 1 decision deadline on May 28, 2026, unless that timetable is extended.